MTOR and cancer: T cell receptor (TCR) engagement with major histocompatibility complexes (MHCs) on cancer cells activates signaling cascades, including the phosphoinositide 3-kinase (PI3K)-AKT-mammalian target of rapamycin (mTOR) pathway, leading to T cell proliferation, cytokine secretion, and cytotoxicity [19,21].